
QuantRx Biomedical Corporation
Share · US74765N1090 (OTC)
No Price
n/a
Company Profile for QuantRx Biomedical Corporation Share
QuantRx Biomedical Corporation engages in the development and commercialization of patented miniform pads (PADs) and PAD based over-the-counter products in the United States. It is also developing genomic diagnostics for the laboratory market based on its lateral flow patents, including RapidSense technology, a one-step lateral flow test. The company's PAD products are used for the treatment of hemorrhoids, minor vaginal infection, urinary incontinence, general catamenial uses, and other medical needs. Its products include InSync, a feminine hygienic interlabial pad; Unique miniform, a treated pad for the temporary relief of the itch and discomfort associated with hemorrhoids and minor vaginal infection, as well as an untreated pad for the daily protection of light urinary, vaginal, or anal leakage; and other treated miniform products. QuantRx Biomedical Corporation was incorporated in 1986 and is based in Tualatin, Oregon.
Company Data
Name QuantRx Biomedical Corporation
Company QuantRx Biomedical Corporation
Primary Exchange
UTC
ISIN US74765N1090
Asset Class Share
Sector Healthcare
Industry Medical - Instruments & Supplies
CEO Shalom Z. Hirschman
Country United States of America
Currency USD
Employees -
Address 10190 SW 90th Avenue, 97062 Tualatin
IPO Date 2004-07-02
ID Changes
| Date | From | To |
|---|---|---|
| 17.02.2006 | AFEM | QTXB |
Ticker Symbols
| Name | Symbol |
|---|---|
| Over The Counter | QTXB |
More Shares
Investors who hold QuantRx Biomedical Corporation also have the following shares in their portfolio:
The financial platform MoneyPeak tracks and analyzes investments and portfolios.
From securities portfolios to crypto purchases.
Useful, simple, and free. Stocks, ETFs, ETCs, ETNs, indices, funds, bonds, certificates, currencies, options, rights issue.
Useful, simple, and free. Stocks, ETFs, ETCs, ETNs, indices, funds, bonds, certificates, currencies, options, rights issue.



